Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Regen BioPharma (RGBP) Other Operating Expenses (2016 - 2025)

Regen BioPharma (RGBP) has disclosed Other Operating Expenses for 13 consecutive years, with $164670.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Operating Expenses rose 81.71% to $164670.0 in Q3 2025 year-over-year; TTM through Dec 2025 was $392862.0, a 3.99% decrease, with the full-year FY2025 number at $488263.0, up 10.67% from a year prior.
  • Other Operating Expenses was $164670.0 for Q3 2025 at Regen BioPharma, up from $69126.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $403680.0 in Q4 2022 to a low of $50711.0 in Q2 2021.
  • A 5-year average of $115271.1 and a median of $92011.0 in 2024 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 240.91% in 2022, then tumbled 69.8% in 2023.
  • Regen BioPharma's Other Operating Expenses stood at $118411.0 in 2021, then surged by 240.91% to $403680.0 in 2022, then crashed by 69.8% to $121900.0 in 2023, then fell by 12.12% to $107126.0 in 2024, then skyrocketed by 53.72% to $164670.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Other Operating Expenses are $164670.0 (Q3 2025), $69126.0 (Q2 2025), and $159066.0 (Q1 2025).